Introduction
Apoptosis, the physiological cell death process, is characterised morphologically by cell shrinkage, chromatin condensation and DNA degradation (Wyllie et al., 1980) . It plays an important role in sculpting tissues during development, in tissue homeostasis and in host defence systems deployed against invading pathogens (Wyllie et al., 1980; Ellis et al., 1991; Vaux and Strasser, 1996) . Since apoptosis triggered by diverse agents can be inhibited by the protein product of the proto-oncogene bcl-2, it seems that several independent biochemical pathways promoting cell death converge upon a common ®nal eector mechanism (Hengartner and Horvitz, 1994a; Cory, 1995; Korsmeyer, 1995; Thompson, 1995; Vaux and Strasser, 1996; White, 1996) .
Studies of cell death in the nematode C. elegans have revealed striking evolutionary conservation of the molecular basis of apoptosis. Two genes, ced-3 and ced-4, are essential for cell death during nematode development while another, ced-9, is essential for cell survival (Ellis et al., 1991; Hengartner et al., 1992; Yuan et al., 1993) . No mammalian ced-4 homologue has been discovered thus far, but ced-3 encodes a cysteine protease related to the interleukin-1b converting enzyme (ICE) (Yuan et al., 1993) and ced-9 is a functional and structural homologue of bcl-2 (Vaux et al., 1992a; Hengartner and Horvitz, 1994b) . Since apoptosis can be induced by overexpression of cysteine proteases (reviewed by Kumar, 1995) and blocked by pseudo-substrate inhibitors encoded by viruses (Gagliardini et al., 1994; Bump et al., 1995) , it appears that cell death is initiated by proteolytic cleavage of one or several critical substrates. Thus, Bcl-2 and Ced-9 may function by blocking a step that leads to the activation or activity of cysteine proteases (Hengartner and Horvitz, 1994a; Cory, 1995; White, 1996) .
Control of cell death appears to be signi®cantly more complex in mammals than in C. elegans. Whilst the nematode apparently has only one cysteine protease gene, ced-3 (Ellis et al., 1991) , there are at least eight in mammals, comprising three distinct subfamilies (Kumar, 1995) . In addition, only one survival gene (ced-9) has been identi®ed in C. elegans, whilst there are three closely homologous genes in vertebrates: bcl-2 (Vaux et al., 1988) , bcl-x L (Boise et al., 1993) and bcl-w (Gibson et al., 1996) , as well as two distantly related genes, A1 (Lin et al., 1996) and Mcl-1 (Reynolds et al., 1994) . Furthermore, in mammals, there exists a sub-family of Bcl-2 homologues, exempli®ed by Bax (Oltvai et al., 1993) , that inhibit the function of the survival proteins by forming heterodimers with them and thereby facilitate cell death when expressed at high levels (Oltvai and Korsmeyer, 1994) . It is presently unclear whether Bax sub-family members participate directly in cell death or merely act as antagonists of proteins of the Bcl-2 sub-family. Baxlike proteins have not yet been found in nematodes but it has been postulated that depending on the genetic make-up of a cell, Ced-9 can either block or promote apoptosis (Hengartner and Horvitz, 1994c) .
Whilst a ced-9 gain of function mutation prevents all developmentally programmed death of somatic cells in C. elegans (Ellis et al., 1991; Hengartner and Horvitz, 1994c) , Bcl-2 is not able to block apoptosis triggered by all physiological cell death stimuli in mammalian cells (reviewed by Strasser, 1995a) . For example, although B and T lymphocytes from bcl-2 transgenic mice are resistant to numerous cytotoxic agents (McDonnell et al., 1989; Sentman et al., 1991; Strasser et al., 1991a Strasser et al., ,b, 1994a , they remain sensitive to apoptosis induced by activation of the surface receptor Fas/APO-1 (CD95) (Strasser et al., 1995c) . Moreover, although bcl-2 transgene expression enhances the survival of immature B and T cells that have failed to receive a survival signal (`death by neglect') (Linette et al., 1994; Strasser et al., 1994b,c) , it is an ineective antidote to`activation induced apoptosis' of lymphocytes bearing autoreactive antigen receptors (Sentman et al., 1991; Strasser et al., , 1994b and does not protect against killing mediated by cytotoxic T cells (Vaux et al., 1992b) . This inability of Bcl-2 to antagonise all pathways to physiological cell death is not restricted to lymphocytes, since its overexpression enhances the survival of sensory neurons deprived of NGF, but does not prevent apoptosis of ciliary neurons deprived of ciliary neurotrophic factor (CNTF) (Allsopp et al., 1993) .
The multiplicity of vertebrate survival proteins (reviewed by Cory, 1995; Korsmeyer, 1995; Thompson, 1995; White, 1996) , raises the possibility that they dier in their ability to block speci®c pathways to apoptosis. For example, dierent cell death-inducing stimuli might activate distinct cysteine proteases, and Bcl-2 and its homologues might selectively inhibit dierent proteases. Alternatively, Bcl-2 and its homologues might be functionally equivalent and all interfere with the cell death machinery at the same point.
Some dierences have been reported in the activities of Bcl-2, Bcl-x L and their adenovirus counterpart, the 19 kD E1B protein. For example, adenovirus E1B19kD protein protected some cultured cell lines against TNF-mediated cytotoxicity (Hashimoto et al., 1991; White et al., 1992) , while Bcl-2 could not (Vanhaesebroeck et al., 1993) , and Bcl-x L enhanced the survival of WEHI-231 B lymphoma cells treated with the immunosuppressive drug cyclosporin A but Bcl-2 was apparently unable to do so (Gottschalk et al., 1994) . Furthermore, some reports documented that neither Bcl-2, Bcl-x L nor E1B19kD can block apoptosis induced via Fas/APO-1 (CD95) in lymphoid cell lines (Memon et al., 1995; Strasser et al., 1995c) while other experiments have demonstrated that all three proteins can provide some protection against Fas/APO-1 (CD95)-and/or TNF receptor-transduced apoptosis in non-lymphoid lines (Hashimoto et al., 1991; White et al., 1992; Itoh et al., 1993; JaÈ aÈ ttelaÈ et al., 1995) . It remains unclear whether these discrepancies are the result of dierences in cell death regulation between dierent cell types or re¯ect functional dierences between members of the Bcl-2 family.
To clarify this issue, we have performed a side-byside comparison of the ability of human Bcl-2, human Bcl-x L and adenovirus E1B19kD protein to inhibit apoptosis triggered by multiple cytotoxic agents in diverse cell lines. The results provide evidence that these three cell death inhibitory proteins are functionally equivalent in their ability to inhibit apoptosis.
Results
In order to compare in a systematic manner the ability of Bcl-2, Bcl-x L and adenovirus protein E1B19kD to promote cell survival, we cloned cDNAs encoding these proteins into the same expression vector ± pEFpGKpuro, a modi®ed pEF Bos vector (Mizushima and Nagata, 1990) (Figure 1 ). To facilitate detection of the transgene-encoded protein, some of the constructs were tagged with an N-terminal FLAG epitope (Hopp et al., 1988) . Pilot experiments demonstrated that FLAGtagged versions of Bcl-2 and its homologues were indistinguishable from their unmodi®ed counterparts in the capacity to inhibit apoptosis induced by cytokine withdrawal or g-irradiation (data not shown). The expression vectors were transfected into cell lines of several types: myeloid, T and B lymphoid, ®broblastoid and epithelioid. Clones expressing comparable levels of Bcl-2, Bcl-x L or E1B19kD were chosen for further investigation. Parental cells and cells transfected with expression vectors containing only the drug resistance gene served as controls.
Comparable levels of Bcl-2, Bcl-x L or adenovirus protein E1B19kD are needed to inhibit cell death induced by growth factor deprivation It has been suggested that all cells within a multi-cellular organism require positive signals from their neighbours for survival and undergo`death by neglect' in their absence (Ra, 1992) . Cultured cell lines undergo apoptosis when deprived of serum or other essential growth factors (Vaux et al., 1988) , as do normal cells such as lymphocytes when they are removed from their in vivo environment and cultured in vitro in the absence of cytokines or mitogens (McDonnell et al., 1989; Sentman et al., 1991; Strasser et al., 1991a,b) . Bcl-2, Bcl-x L or E1B19kD have all been shown to inhibit apoptosis of many cell types deprived of growth factors (reviewed by Cory, 1995; Korsmeyer, 1995; Thompson, 1995; White, 1996) , but no systematic study has been performed to see if they are equally eective.
To address this issue, we selected FDC-P1 clones expressing dierent levels of FLAG-tagged Bcl-2, Bcl-x L or E1B19kD protein (Figure 2a Nagata, 1990) was modi®ed by the introduction of the puromycin resistance gene (driven by the pGK promoter) and an N-terminal FLAG epitope (see Materials and methods). Polycloning sites (BamHI, ClaI, SalI, EcoRV, NotI and XbaI) allow in-frame fusion with any cDNA of interest die by apoptosis within 48 h of removing the cytokine. The level of protection aorded by each survival protein was found to be related to the level of expression and each was about as eective as the other at a given concentration (Figure 2d ± f) . Three days after IL-3 withdrawal, the survival of clones expressing medium or high levels (relative¯uorescence intensity, RFI: *20 or *40) of Bcl-2, Bcl-x L or E1B19kD was signi®cantly greater than that of clones expressing low levels (RFI: 5 ± 6) (485% vs 20 ± 40%) (Figure 2d ± f).
Bcl-2, Bcl-x L and E1B19kD protect cells against the same spectrum of apoptosis inducers
To test whether Bcl-2, Bcl-x L and adenovirus protein E1B19kD diered in their ability to antagonise distinct apoptosis signal transduction pathways, we compared their impact in several cell lines exposed to g-radiation, DNA damage inducing drugs used in chemotherapy, corticosteroids and staurosporine.
Each of the proteins signi®cantly increased the gradiation resistance of all cell lines tested: B6.2.16BW2 T hybridoma cells, CH1 B lymphoma cells, KO52DA20 thymic lymphoma cells (although E1B19kD was not tested in the latter two), WEHI-164 ®brosarcoma cells and FDC-P1 myeloid cells (Figure 3a ± d, data not shown and Table 1 ). Each also antagonised dexamethasone-induced apoptosis (30-to 100-fold protection) in B6.2.16BW2 T hybridoma cells ( Figure 3e and Table 1 ) and KO52DA20 thymoma cells (not shown) and greatly enhanced the resistance to the protein kinase inhibitor staurosporine (50-to 100-fold) in WEHI-164 fibrosarcoma cells (Figure 3f In addition, the survival proteins were indistinguishable in their ability to inhibit apoptosis induced by ceramide, peroxide, cycloheximide, bleomycin, etoposide, cisplatin and mitomycin C (data not shown). Upper panels show examples of clones expressing low (lo), medium (med) and high (hi) levels of (a) FLAG-tagged human Bcl-2, (b) human Bcl-x L or (c) adenovirus E1B19kD protein; immuno¯uorescence staining was performed with a monoclonal antibody (M2) speci®c for the FLAG epitope. Lower panels show the impact of low, medium and high levels of (d) FLAG-Bcl-2, (e) FLAG-Bcl-x L or (f) FLAG-E1B19kD on survival of FDC-P1 cells deprived of IL-3. Data are arithmetic means+s.d. of three independent clones of each genotype and are representative of three or more experiments 
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Collectively, these results indicate that Bcl-2, Bcl-x L and adenovirus protein E1B19kD are equipotent in antagonising diverse pathways to apoptosis in a broad range of cell types.
Bcl-2, Bcl-x L and adenovirus protein E1B19kD inhibit cell killing by cyclosporin A
The immunosuppressive drug cyclosporin A binds to a group of cellular target proteins, called immunophilins, and thereby blocks antigen induced activation of mature T lymphocytes (reviewed by Sigal and Dumont, 1992) . It has been reported that cyclosporin A induces apoptosis of WEHI-231 mouse B lymphoma cells and that this can be blocked by Bcl-x L but not by Bcl-2 (Gottschalk et al., 1994) . We found, however, that Bcl-2 was just as protective as Bcl-x L (Figure 4a ). Furthermore, Bcl-2 protected CH1 B lymphoma cells ( Figure 4b ) and Bcl-2, Bcl-x L and E1B19kD were all eective in protecting B6.2.16BW2 T hybridoma cells and WEHI-164 ®brosarcoma cells (Figure 4c and d) .
No signi®cant dierence could be detected between the three proteins either in the kinetics of cell survival (Figure 4a ± d) or the sensitivity to dierent levels of the drug (data not shown).
Lines that expressed the highest levels of Bcl-2, Bcl-x L or E1B19kD were chosen for these experiments. Functional analysis on the epitope-tagged versions of the same proteins (Figure 2 ) indicated that we were able to express comparably high levels of the transgene-encoded protein using a common vector based on the pEF Bos vector. Therefore, we suggest that the dierence previously reported between Bcl-2 and Bcl-x L (Gottschalk et al., 1994) was likely to be due to dierent levels of protein expression achieved.
Bcl-2, Bcl-x L and E1B19kD are ineective antagonists of Fas/APO-1 (CD95)-or TNF receptor-induced cell killing
The ability of members of the Bcl-2 protein family to modulate Fas/APO-1 (CD95)-or TNF receptortransduced cell death is controversial. We therefore compared the impact of Bcl-2, Bcl-x L and E1B19kD in several cell lines susceptible to apoptosis induction by anti-Fas/APO-1 (CD95) antibody (Figure 5) or TNF ( Figure 6 ). None of the three proteins was able to reduce the sensitivity of SKW6 human B lymphoblastoid cells to Fas/APO-1 (CD95) induced death or Figure 3 Bcl-2, Bcl-x L and adenovirus protein E1B19kD are equivalent in their ability to inhibit apoptosis triggered by diverse cytotoxic stimuli in several cell types. The impact of overexpression of Bcl-2, Bcl-x L and adenovirus E1B19kD protein on apoptosis of the mouse T hybridoma cell line B6.2.16.BW2 (a, e), the mouse B lymphoma cell line CH1 (b), the mouse ®brosarcoma line WEHI-164 (c, f) and the mouse thymoma line KO52DA20 (d) by treatment with (a ± d) g-radiation, (e) dexamethasone or (f) staurosporine is shown. Data are representative of three or more experiments and are arithmetic means+s.d. from three independent clones, chosen on the basis of highest protein expression as shown by¯ow cytometric analysis, of each genotype. Experiments were performed with lines expressing Bcl-2, FLAG-Bcl-2, FLAG-Bcl-x L , E1B19kD and FLAG-E1B19kD
Functional equivalence of Bcl-2, Bcl-x L and E1B19kD DCS Huang et al modulate its kinetics (Figure 5b ), even though they substantially enhanced resistance to staurosporine (Figure 5a ). Similarly, CH1 B lymphoma cells expressing either Bcl-2 or Bcl-x L remained susceptible to Fas/APO-1 (CD95) induced death (Figure 5d ), as reported previously for Bcl-2 (Strasser et al., 1995c) , even though they were signi®cantly resistant (20-to 50-fold) to serum withdrawal (Figure 5c ). Multiple independently derived cell lines were tested in these experiments. Furthermore, while protection against staurosporine-induced death of SKW6 cells or serum withdrawal in CH1 cells was dependent on the level of protein expression of Bcl-2 or its homologues, none of these lines showed any dierences in their susceptibility to death induced by Fas-APO-1 (CD95) (data not shown). TNF-induced cell death was unaected by expression of Bcl-2, Bcl-x L or E1B19kD in the mouse ®broblastoid line L929 (Figure 6a ) and in NIH3T3 ®broblasts (data not shown), in accordance with previous data for Bcl-2 (Vanhaesebroeck et al., 1993) . Each of the three survival proteins did, however, protect these cells from apoptosis induced by heat shock (Strasser and Anderson, 1995) , serum withdrawal or staurosporine (data not shown). While they conferred some degree of protection against TNF in the human breast carcinoma line MCF-7 ( Figure  6b ) and in the mouse ®brosarcoma line WEHI-164 (Figure 6c) , the level was modest (1.5 ± 3-fold), in marked contrast to the almost complete (450-fold) protection aorded against staurosporine-induced apoptosis (Figure 3f and data not shown). Collectively, these results demonstrate that Bcl-2, Bcl-x L and E1B19kD are all ineective inhibitors of Fas/APO-1 (CD95)-and TNF receptor-induced cell death.
Bcl-2, Bcl-x L and E1B19kD can associate with Bax and Bak
Although we detected no signi®cant dierences in their capacity to inhibit apoptosis, it was possible that the three survival proteins interacted with dierent intracellular partners. We therefore examined their ability to bind to the Bax sub-family or proteins. Immunoblot analysis of immunoprecipitated extracts of transfected cells reveals that Bcl-2, Bcl-x L and E1B19kD can each bind to both Bax and Bak (Figure 7) . Although it has been suggested that Bcl-2 may have a lower anity for Bax or Bak, we could not con®rm these results in our overexpression studies. However, these results provide evidence that each of these three survival proteins interacts with at least some components of the cell death eector machinery.
Discussion
It has been controversial whether Bcl-2 homologues that inhibit apoptosis are functionally equivalent, and whether they can antagonise all or only some pathways leading to cell death. We have directly compared, in the same cell types and using the same vector, the biological activity of human Bcl-2, human Bcl-x L and adenovirus protein E1B19kD. Our data indicate that these proteins are functionally equivalent in a wide range of cell types, at least at the high levels of expression achieved, and that they are eective against many but not all mediators of apoptosis.
Overexpression of Bcl-2, Bcl-x L or E1B19kD protein greatly increased (up to 200-fold) the survival of several types of tissue culture lines (myeloid, lymphoid and ®broblastoid) upon deprivation of growth factor or serum (e.g. Figures 2 and 5 and Table 1 ). We speculate that this pathway to apoptosis is related to the one that is physiologically activated in normal cells undergoing`death by neglect' in vivo, a process known to be potently antagonised by Bcl-2 (Linette et al., 1994; Strasser et al., 1994b,c) .
Bcl-2, Bcl-x L and E1B19kD were indistinguishable in their ability to protect cell lines against the toxic eects of a broad range of other cytotoxic conditions including treatment with staurosporine, ceramide, peroxide, cycloheximide, dexamethasone, g-radiation and DNA damaging drugs such as bleomycin, cisplatin, mitomycin C and etoposide (e.g. see Figures  3 and 4 and Table 1 ). These data extend previous observations that each of these proteins inhibits corticosteroid induced apoptosis in mouse T hybridoma cells (Memon et al., 1995) and that transgenic expression of bcl-2 and bcl-x L endow lymphocytes with comparable resistance to corticosteroids and g-radiation (Sentman et al., 1991; Chao et al., 1995; Grillot et al., 1995) . Of particular note, and contrary to a previous report (Gottschalk et al., Functional equivalence of Bcl-2, Bcl-x L and E1B19kD DCS Huang et al 1994), Bcl-2 was just as eective as Bcl-x L in protecting cells from apoptosis induced by cyclosporin A, as was E1B19kD protein (Figure 4) .
In contrast to the signi®cant inhibition aorded by all three survival proteins against the aforementioned cell death inducing stimuli, they proved to be ineective suppressors of Fas/APO-1 (CD95)-or TNF receptor-transduced apoptosis ( Figures 5 and 6 and Table 1 ). Similar conclusions have been reached by other studies on a number of cell lines or lymphocytes from transgenic mice (Memon et al., 1995; Strasser et al., 1995c) . Moreover, crossing of bcl-2 transgenic mice onto the Fas/APO-1 (CD95)-de®cient lpr background revealed that gain of Bcl-2 and loss of Fas/APO-1 (CD95) synergise in promoting lymphocyte accumulation, indicating that these two molecules regulate distinct pathways to lymphocyte apoptosis (Reap et al., 1995; Strasser et al., 1995c) . Although in certain cell lines and hepatocytes of transgenic mice, Bcl-2 and certain homologues have been documented to provide some measure of protection ( Figure 6 ) and (Hashimoto et al., 1991; White et al., 1992; Itoh et al., 1993; JaÈ aÈ ttelaÈ et al., 1995; Lacronique et al., 1996; Rodriguez et al., 1996) , the eects have been modest at best. In our experiments, it is clear that levels of expression that aord substantial protection, in a dose-dependent manner, against serum deprivation or treatment with staurosporine only weakly inhibited death induced by the Fas/APO-1 (CD95) ligand or TNF (for example, compare data for WEHI-164 cells between Figure 3f to data in Figure 6c , and for SKW6 and CH1 cells in Figure 5 ). The possibility that induction of dominant repressors of Bcl-2 survival proteins accounts for this dierence seems unlikely in view of evidence presented elsewhere that the levels of Bax and Bcl-x S are not increased in response to Fas/APO-1 (CD95) activation in two B lymphoid cell lines (Strasser et al., 1995c) . We therefore favour the hypothesis that the principal pathway triggered by TNF receptors and Fas/APO-1 (CD95) activation bypasses the Bcl-2-sensitive step. Figure 8 presents a model for the circuitry of cell death that would account for these observations. In essence, it proposes that there are at least two distinct pathways to apoptosis which can be distinguished by whether or not they are regulated by members of the Bcl-2 family. The pathway initiated by Fas/APO-1 (CD95) and TNF-R1 (B in Figure 8 ), activates ICE and lacks a Bcl-2-sensitive step. In contrast, pathways activated by many other cytotoxic conditions (A in Figure 8 ), include a step that is inhibitable by Bcl-2 (or its homologues). These pathways probably do not require ICE or a closely related protease and are postulated to activate a dierent class of cysteine Functional equivalence of Bcl-2, Bcl-x L and E1B19kD DCS Huang et al protease (X in Figure 8 ) instead. There is increasing evidence to support this model. It has been demonstrated in several cell lines (Memon et al., 1995; Strasser et al., 1995c) and in T lymphocytes of transgenic mice (Smith et al., 1996) that Bcl-2 and CrmA, the cowpox virus serpin-like inhibitor speci®c for ICE (and perhaps its closest homologues) (Bump et al., 1995; Nicholson et al., 1995) antagonise dierent pathways: Bcl-2 inhibits apoptosis induced by growth factor withdrawal, treatment with dexamethasone, g-radiation or staurosporine but not that provoked by Fas/APO-1 (CD95), whereas CrmA does the opposite. Furthermore, thymocytes from ICE 7/7 mice are resistant to Fas/APO-1 (CD95)-induced death but remain sensitive to growth factor withdrawal, g-radiation and corticosteroids (Kuida et al., 1995) . Finally, apoptosis induced by transient over- 5 and 9 ) or co-transfected with Bak and vectors expressing FLAG-Bcl-2 (lanes 2 and 6), FLAG-Bcl-x L (lanes 3 and 7) or FLAG-E1B19kD (lanes 4 and 8) using polyclonal anti-Bak antibody Figure 8 Model of signal transduction pathways for apoptosis. Apoptosis is probably induced by at least two independent pathways, (A) and (B), which converge. The Bcl-2 family acts only on branch A, including apoptosis induced by the tumour suppressor protein p53. The cysteine protease ICE is activated by pathway B but not by pathway A. Cowpox virus CrmA acts as a pseudosubstrate for ICE (Nicholson et al., 1995) , and thereby inhibits Fas/APO-1 (CD95)-induced apoptosis. X and Y denote other ICE-like cysteine proteases, synthesised as inactive precursors, and the model predicts that both are refractory to inhibition by CrmA (Nicholson et al., 1995) . Baculovirus p35 is a psuedosubstrate for many, perhaps all, ICE-like cysteine proteases (Xue and Horvtiz, 1995) . RIP and FADD (acting via FLICE (Boldin et al., 1996; Muzio et al., 1996) ) are cytoplasmic transducers of the Fas/APO-1 (CD95) apoptosis signal and TRADD (Hsu et al., 1995) transduces the TNFR1 signal, via FADD. To account for synergy displayed by CrmA and Bcl-2 in blocking Fas/APO-1 (CD95)-induced apoptosis (Strasser et al., 1995c; Smith et al., 1996) , Fas/APO-1 (CD95) is postulated to activate at least two apoptotic pathways
Functional equivalence of Bcl-2, Bcl-x L and E1B19kD DCS Huang et al expression of TRADD, a cytoplasmic signal transducing protein that binds to the 55 kD TNF receptor via interaction between`death domains', is inhibited by CrmA but not by Bcl-2 or E1B19kD protein (Hsu et al., 1995) . The Bcl-2-sensitive and -insensitive death pathways may converge if they ultimately activate the same protease (Y in Figure 8 ). Consistent with this hypothesis, CrmA-sensitive cysteine proteases can activate those that are CrmA-insensitive and, during Fas/APO-1 (CD95)-mediated apoptosis, activation of a (CrmA-sensitive) ICE-like protease precedes that of a (CrmA-insensitive) CPP32-like protease (Enari et al., 1996) . Protease Y in Figure 8 may therefore be a member of the CPP32/Yama sub-family of cysteine proteases, two members of which have been shown to be cleaved in cells treated with either anti-Fas/APO-1 (CD95) antibodies or staurosporine .
The mechanism of signal transduction by Fas/APO-1 (CD95) and TNF-R1 is beginning to emerge. FADD (Mort 1), which can interact with both thè death domain' of Fas/APO-1 (CD95) (Boldin et al., 1995; Chinnaiyan et al., 1995) and that of TRADD (Hsu et al., 1996) , appears to play a central role in transducing the signals from both receptors. The Nterminal region of FADD (Mort 1) is essential for its ability to induce apoptosis (Hsu et al., 1996) and can recruit a cysteine protease, termed FLICE or MACH (Boldin et al., 1996; Muzio et al., 1996) , directly to Fas/APO-1 (CD95) and the p55 TNF receptor complexes. Further investigation of the function of these signal transducing protein(s) may clarify why pathway B in Figure 8 is resistant to Bcl-2 and its homologues.
In view of the fact that Bcl-2 and its functional homologues are equivalent in their ability to inhibit cell death, what is the physiological reason for having several of these proteins in mammalian cells? The patterns and levels of expression of Bcl-2, Bcl-x L and Bcl-w are not identical (Hockenberry et al., 1991; LeBrun et al., 1993; Gonzalez-Garcia et al., 1994; Gibson et al., 1996) and these dierences may re¯ect the need to ®ne-tune the control of apoptosis in a cell type-and dierentiation type-speci®c manner. Consistent with this hypothesis Bcl-2-de®cient and Bcl-x-de®cient mice exhibit distinct phenotypic abnormalities (Veis et al., 1993; Motoyama et al., 1995) .
A major challenge for the future is to identify the biochemical reaction regulated by Bcl-2 and its survival-promoting homologues. Overexpression of these proteins greatly increases the clonogenic survival of at least some tumour cells (Strasser et al., 1994a) and deregulated expression of bcl-2 is lymphomagenic (McDonnell and Korsmeyer, 1991; Strasser et al., 1993; Linette et al., 1995) , especially in conjunction with overexpression of proto-oncogenes that promote cell proliferation, such as c-myc and pim-1 (Strasser et al., 1990; Acton et al., 1992) . The development of an antagonist capable of inhibiting all functional homologues of Bcl-2 and thereby enhancing sensitivity to apoptosis therefore holds great promise for the treatment of neoplastic disease, particularly in combination with other therapeutic regimes. Conversely, an agonist of Bcl-2 and its homologues may oer therapeutic bene®t for a variety of degenerative diseases.
Materials and methods

Cell lines and expression constructs
FDC-P1 is a mouse IL-3-dependent promyelocytic cell line; B6.2.16BW2, a mouse T cell hybridoma; KO52DA20, a thymoma line derived from a p53 7/7 mouse; WEHI-164, a chemical carcinogen-induced mouse ®brosarcoma line; L929 and NIH3T3, mouse ®broblastoid lines; CH1 and WEHI-231, mouse B lymphoma lines; SKW6, a human B lymphoblastoid cell line; Jurkat, a human T lymphoma line and MCF-7, a human breast carcinoma line (for references see Lithgow et al., 1994; Strasser et al., 1994a Strasser et al., , 1995c . All cell lines were cultured in the high glucose version of Dulbecco's modi®ed Eagle's (DME) medium supplemented with 10% foetal calf serum, 50 mM 2-mercaptoethanol, 13 mM folic acid and 100 mM L-asparagine.
The pEF FLAGpGKpuro expression vectors were modi®ed from the vectors pPGKbgeopA, pBabePuro (Morgenstern and Land, 1990 ) and pEF Bos (Mizushima and Nagata, 1990) . The bgeo cDNA in pPGKbgeopA was replaced by the puromycin resistance gene from pBabePuro to make pPGKpuro. Then a PvuII blunt fragment from pEF Bos (containing the SV40 origin, EF-1a promoter, polycloning sites and a polyA region) was inserted into pPGKpuro to make pEF pGKpuro. The N-terminal FLAG tag (Hopp et al., 1988) , encoding the sequence MDYKDDDDK, was inserted by PCR and a Kozak consensus sequence was also inserted 5'-to the tag. Three dierent versions of the vector were made to allow for fusions of cDNAs in all three reading frames. All the vectors were sequenced to verify the construct.
Cell lines were transfected by electroporation using a Gene-pulser (Biorad) with control vectors (pEFMC1neo) or (pEFpGKpuro and pEF FLAGpGKpuro) or vectors containing human Bcl-2, Bcl-x L or adenovirus E1B19kD cDNAs (with or without the FLAG tag (Hopp et al., 1988) ). Transfectants were selected by growth in G418 (1 ± 2 mg/ml) or puromycin (2 ± 5 mg/ml). Cell lines were single cell cloned using limiting dilution culture or the¯uorescence activated cell deposition unit of the FACStarPlus (Becton Dickinson). Clones expressing high levels of the protein of interest were identi®ed by immuno¯uorescence staining of permeabilised, ®xed cells and¯ow cytometric analysis. For some experiments, we also included cell lines that had been infected either with a control neo or with a bcl-2/neo retrovirus (Vaux et al., 1988; Lithgow et al., 1994) .
Cell death and cell cycle analysis
Cytotoxicity was tested in vitro with anti-human Fas/APO-1 (CD95) monoclonal antibody APO-1 (Trauth et al., 1989) and anti-mouse Fas/APO-1 (CD95) monoclonal antibody Jo2 (Pharmingen, San Diego, CA; Ogasawara et al., 1993) within the concentration range of 10 74 ± 10 mg/ml; 1 ± 1000 ng/ml recombinant human TNF (a kind gift from G Wong, Genentech), either in the presence or absence of 25 mg/ml cycloheximide (Sigma); 2 ng/ml phorbol 12-myristate 13-acetate (PMA) (Sigma); 1 mg/ml ionomycin (Sigma); 1 mM dexamethasone (Sigma); 1 ± 10 mM staurosporine (Sigma); or g-radiation with 1000 rad. g-radiation was provided by a 60 Co source at a rate of 300 rad/min. Cell viability was determined either by trypan blue exclusion and counting in a haemocytometer or by¯ow cytometric anlaysis of cells stained with 5 mg/ml propidium iodide (PI, Sigma) using a FACScan (Becton Dickinson, Mountain View, CA).
Functional equivalence of Bcl-2, Bcl-x L and E1B19kD DCS Huang et al Apoptotic cells were quanti®ed by¯ow cytometry (Nicoletti et al., 1991) . Cells were stained for 30 min at 48C with 50 mg/ml propidium iodide (PI, Sigma) in 0.1% sodium acetate with 0.2% Triton X100 (BDH Chemicals, UK) and stained cells were analysed in the FACScan. Debris was excluded on the basis of the forward and side light scattering properties. Cells undergoing apoptosis have a characteristic PI-staining pro®le with an apparent DNA content of less than 2C.
Immuno¯uorescence staining and¯ow cytometric analysis
For cytoplasmic staining of Bcl-2 or its homologues, cells were ®xed for 5 min in 80% methanol at 7208C or for 10 min in 1% paraformaldehyde at room temperature and permeabilised with 0.3% saponin (Sigma), which was included in all subsequent staining and washing steps. The cells were ®rst stained for 40 min on ice with 2 mg/ml of the monoclonal antibodies Bcl-2-100 (mouse anti-human Bcl-2; (Pezzella et al., 1990) ), rat anti-E1B19kD (Oncogene Science) or mouse anti-FLAG M2 monoclonal antibody (IBI) and then with¯uorescein-isothiocyanate (FITC)-conjugated goat anti-mouse IgG (1 mg/ml; Southern Biotechnology) or FITC-conjugated goat anti-rat IgG (1 mg/ml; Southern Biotechnology) antibodies as secondary reagents. Cells were analysed in the FACScan, live and dead cells being discriminated on the basis of their forward and side light-scattering properties.
Immunoprecipitation
To test for physical interaction between proteins in vivo, 3610 6 FDC-P1 cells (or 0.5610 6 COS cells) were lysed for 20 min on ice under gentle detergent conditions in lysis buer (®nal concentration ± 50 mM pH 7.4, Tris-HCl, 1% NP-40, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM EGTA, 1 mM PMSF, 100 mg/ml soy bean trypsin inhibitor and 1 mg/ml pepstatin, leupeptin and aprotinin). Lysates were precleared twice for 42 h at 48C with protein G Sepharose beads (Pharmacia) followed by immunoprecipitation with 5 mg of the anti-FLAG M2 monoclonal antibody for each lysate. The immunoprecipitate was then captured with protein G sepharose, washed ®ve times with lysis buer and once with PBS, boiled and then resolved on a 12.5% SDS-polyacrylamide gel.
SDS gel electrophoresis and Western blotting
Proteins were solubilised from control and transfected cells (or from sepharose beads after immunoprecipitation) by lysis in gel running buer (0.25 M Tris-HCl, pH 6.8; 1% SDS; 20% glycerol; 5% 2-mercaptoethanol; 0.02% bromophenol blue), boiled for 10 min, size fractionated on 12.5 or 15% SDS-polyacrylamide gels and then transferred to nitrocellulose membranes by electroblotting. After blocking (41 h at room temperature in 5% skim milk, 1% foetal bovine serum, 1% casein), membranes were incubated (42 h at room temperature) with antibodies (2 mg/ml) speci®c for human Bcl-2 (see above for clones), with a rabbit antiserum (dilution 1/200 to 1/500) speci®c for mouse Bax (raised against an Nterminal murine Bax peptide: Ac-GSGEQLGSGGPTSSC-NH2), or with rabbit antiserum TC98 speci®c for human Bak (a gift from G Evan). When mouse monoclonal antibodies were used as primary reagents, membranes were subsequently incubated (41 h at room temperature) with 5 mg/ml anity-puri®ed rabbit anti-mouse IgG (Fcgspeci®c) (Jackson Immuno Research). Membranes were probed (41 h at room temperature) with 125 I-labelled protein A (1 ± 2610 6 c.p.m./ml).
